Biomedind (quadruple) Even Better Answer to Novo Nordisk's Answer to Retatrutide.? NA-931

[DjJoshua]

I just had to post his,

What is NA-931 , a quadruple receptor agonist ?

NA-931 is the first in class, a quadruple receptors agonist of IGF-1, GLP-1, GIP and Glucagon.

Here is the link to the item and all the things they claim it could do... Maybe the guys in China can get working on a knock off asap?

NA-931

NA-931 is for the treatment Diabetes Obesity and Alcohol Use Disorder

www.biomedind.com

 

[Habibibi]

Vaporware

The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog

In this article, I'm going to present multiple lines of evidence to explain why I think NA-931, marketed as Bioglutide, doesn't exist, and that Lloyd L. Tran

ausaminos.com

Ask yourself why you're just hearing about it now.

Ask yourself why no other company has been able to offer even a dual agonist as an oral small molecule.

Ask yourself why you haven't heard this company being in acquisition talks.

 

[DjJoshua]

Vaporware

The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog

In this article, I'm going to present multiple lines of evidence to explain why I think NA-931, marketed as Bioglutide, doesn't exist, and that Lloyd L. Tran

ausaminos.com

Ask yourself why you're just hearing about it now.

Ask yourself why no other company has been able to offer even a dual agonist as an oral small molecule.

Ask yourself why you haven't heard this company being in acquisition talks.

Overall, this tracks like a typical early-to-mid-stage biotech asset, Promising Phase 2 data presented publicly, registered trials, recent JPM hype for funding/visibility and clear next steps into Phase 3. It's not sitting stagnant for years without evidence. If trials deliver (especially on muscle preservation), it could be a real contender in the oral obesity space.

ClinicalTrials.gov listings

(official U.S. registry): Multiple active or recently completed entries sponsored by Biomed Industries, including:
NCT06564753: Phase 2 trial for obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; 13-week study evaluating safety, weight loss, etc.).

NCT06615700: Phase 1 dose-escalation study for safety, PK/PD in obese participants and T2DM patients.

NCT06732245: Phase 2 evaluating NA-931 alone or added to tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These are not placeholders—details include study designs, start/completion estimates (e.g., some with 2025–2026 timelines), and sponsor info.

Recent public updates and presentations:
Phase 2 topline results presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).

Company press releases (via EIN Presswire and their site) from mid-2025 onward highlight these as breakthroughs, with claims of significant weight loss without muscle loss due to the IGF-1 component.

January 2026 announcements (during JPM Healthcare Week): Plans to initiate two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, focusing on durable weight loss and lean-mass preservation.

 

[latviantower]

Overall, this tracks like a typical early-to-mid-stage biotech asset, Promising Phase 2 data presented publicly, registered trials, recent JPM hype for funding/visibility and clear next steps into Phase 3. It's not sitting stagnant for years without evidence. If trials deliver (especially on muscle preservation), it could be a real contender in the oral obesity space.

ClinicalTrials.gov listings

(official U.S. registry): Multiple active or recently completed entries sponsored by Biomed Industries, including:
NCT06564753: Phase 2 trial for obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; 13-week study evaluating safety, weight loss, etc.).

NCT06615700: Phase 1 dose-escalation study for safety, PK/PD in obese participants and T2DM patients.

NCT06732245: Phase 2 evaluating NA-931 alone or added to tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These are not placeholders—details include study designs, start/completion estimates (e.g., some with 2025–2026 timelines), and sponsor info.

Recent public updates and presentations:
Phase 2 topline results presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).

Company press releases (via EIN Presswire and their site) from mid-2025 onward highlight these as breakthroughs, with claims of significant weight loss without muscle loss due to the IGF-1 component.

January 2026 announcements (during JPM Healthcare Week): Plans to initiate two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, focusing on durable weight loss and lean-mass preservation.

Yeah crickets since last year on this. High level scam?

 

[Jerrey]

Yeah crickets since last year on this. High level scam?

I have to agree making press releases in order to inspire a flood of investment capital is pretty common tactic. I will be a bit surprised if ongoing testing proves their, pie in the sky, results to continue in the rest of the trials.

 

[Lyophilized]

I'm already in phase I "octuple" agonist receptor : Reta + Tirz + BPC157 + KPV + GHK-Cu

Joke aside, everything of new molecules info, for me, is always appreciated

 

[Habibibi]

Overall, this tracks like a typical early-to-mid-stage biotech asset, Promising Phase 2 data presented publicly, registered trials, recent JPM hype for funding/visibility and clear next steps into Phase 3. It's not sitting stagnant for years without evidence. If trials deliver (especially on muscle preservation), it could be a real contender in the oral obesity space.

ClinicalTrials.gov listings

(official U.S. registry): Multiple active or recently completed entries sponsored by Biomed Industries, including:
NCT06564753: Phase 2 trial for obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; 13-week study evaluating safety, weight loss, etc.).

NCT06615700: Phase 1 dose-escalation study for safety, PK/PD in obese participants and T2DM patients.

NCT06732245: Phase 2 evaluating NA-931 alone or added to tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These are not placeholders—details include study designs, start/completion estimates (e.g., some with 2025–2026 timelines), and sponsor info.

Recent public updates and presentations:
Phase 2 topline results presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).

Company press releases (via EIN Presswire and their site) from mid-2025 onward highlight these as breakthroughs, with claims of significant weight loss without muscle loss due to the IGF-1 component.

January 2026 announcements (during JPM Healthcare Week): Plans to initiate two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, focusing on durable weight loss and lean-mass preservation.

Actually it's the top line results presentation last year that seems to confirm it. Someone that attended one of these conferences (and is a clinician that knows a lot of about GLP1s ) attended their presentation and saw several red flags.

Also, why do they need synergy with tirzepatide or semaglutide? If this thing works so well, it should blow both of them out of the water.